Related Experiment Video
Updated: Jul 30, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Completeness of reporting in abstracts of randomized controlled trials assessing interventional radiology for liver
Jules Grégory1, Cesare Maino2, Valérie Vilgrain3
1Université Paris cité, INSERM, INRAE, CNAM, CRESS, Paris, France; Department of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, France; FHU MOSAIC, APHP, Clichy, France.
Purpose:
To assess the completeness of reporting in abstracts of published randomized controlled trials (RCTs) assessing interventional radiology (IR) for liver disease; to assess whether publication of the 2017 CONSORT update for nonpharmacological treatments (NPT) resulted in changes in abstract reporting; and to identify factors associated with better reporting.
Material And Methods:
MEDLINE and Embase were searched to identify RCTs of IR for liver disease (January 2015-September 2020). Two reviewers assessed the completeness of abstract reporting according to the CONSORT-NPT-2017-update. The primary outcome was the mean number of CONSORT items completely reported among 10 items reported in <50% of the abstracts published in 2015. A time series analysis assessed the evolution trend over time. A multivariate regression model was used to identify factors associated with better reporting.
Results:
A total of 107 abstracts of RCTs published in 61 journals were included. Overall, 74% (45/61) of journals endorsed the main CONSORT guidelines, of which 60% (27/45) had a policy to implement them. The mean number of primary outcome items completely reported increased by 0.19 over the study period. The publication of the CONSORT-NPT update did not lead to an increase in the trend of items reported (increase of 0.04 items/month before vs. 0.02 after, P=0.41). Factors associated with more complete reporting were impact factor (OR=1.13; 95%CI:1.07-1.18) and endorsement of CONSORT with an implementation policy (OR=8.29; 95%CI:2.04-33.65).
Conclusion:
Completeness of reporting is incomplete in abstracts of trials of IR liver disease and did not improve after publication of the CONSORT-NPT-2017 update with abstract guidance.
